Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice

Cancer Research

Volumn 71, Issue 11, 2011, Pages 3952-3962

  Wozniak, Krystyna M ^a   Nomoto, Kenichi ^c   Lapidus, Rena G ^b   Wu, Ying ^a   Carozzi, Valentina ^e   Cavaletti, Guido ^e   Hayakawa, Kazuhiro ^f   Hosokawa, Satoru ^f   Towle, Murray J ^c   Littlefield, Bruce A ^d   Slusher, Barbara S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^c EISAI INC   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ERIBULIN; IXABEPILONE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; MAXIMUM TOLERATED DOSE; MOUSE; NERVE CONDUCTION DISORDER; NERVE FIBER DEGENERATION; NERVE POTENTIAL; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SCIATIC NERVE; SPINAL GANGLION; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOTHILONES; FEMALE; FURANS; GANGLIA, SPINAL; KETONES; MESYLATES; MICE; MICE, INBRED BALB C; NEURAL CONDUCTION; PACLITAXEL; POLYNEUROPATHIES; RATS; SCIATIC NERVE; TUBULIN MODULATORS;

EID: 79957906209     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-4184     Document Type: Article

References (44)

1. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al., (eds). SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute; 2009. [http://seer.cancer.gov/csr/1975-2007/]
2. Perez EA. Paclitaxel in breast cancer. Oncologist 1998;3:373-89. (Pubitemid 29009301)
3. Kuroi K, Shimozuma K. Neurotoxicity of taxanes: symptoms and quality of life assessment. Breast Cancer 2004;11:92-9.
4. Guastalla JP 3rd, Dieras V. The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer 2003;89 Suppl 3S16-22.
5. Bokhari F, Sawatzky JV. Chronic neuropathic pain in women after breast cancer treatment. Pain Manag Nurs 2009;10:197-205.
6. Lee FY, Covello KL, Castaneda S, Hawken DR, Kan D, Lewin A, et al. Synergistic antitumor activity of ixabepilone (BMS-227550) plus bevacizumab in multiple in vivo tumor models. Clin Cancer Res 2008;14: 8123-31.
7. Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol 2008;63:157-66.
8. Hunt JT. Discovery of ixabepilone. Mol Cancer Ther 2009;8:275-81.
9. Steinberg M. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer. Clin Ther 2008;30:1590-617.
10. Perez EAMicrotubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity and resistance. Mol Cancer Ther 2009;8:2086-95.
11. Hagiwara H, Sunada Y. Mechanism of taxane neurotoxicity. Breast Cancer 2004;11:82-5.
12. Lee JJ, Swain SM. Peripheral neuropathy induced my microtubule stabilizing agents. J Clin Oncol 2006;24:1633-42. (Pubitemid 46638788)
13. Canta A, Chiorazzi A, Cavaletti G. Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system. Curr Med Chem 2009;16:1315-24.
14. Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009;27:2954-61.
15. Twelves C, Cortes J, Vahdat LT, Wanders J, Akerele C, Kaufman PA. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer 2010;10:160-3.
16. Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 2010;49:1331-7.
17. Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001;61:1013-21.
18. Cigler T, Vahdat LT. Eribulin mesylate for the treatment of breast cancer. Expert Opin Pharmacother 2010;11:1587-93.
19. Mimura Y, Kato H, Eguchi K, Ogawa T. Schedule dependency of paclitaxel-induced neuropathy in mice: a morphological study. Neurotoxicology 2000;1:513-20.
20. Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 2009;63:201-12.
21. Cavaletti G, Petruccioli MG, Tredici G, Marmiroli P, Barajon I, Fabbrica D, et al. Effects of repeated administration of low doses of cisplatin on the rat nervous system. Int J Tissue React 1991;13:151-7.
22. Cavaletti G, Tredici G, Marmirioli P, Petruccioli MG, Barajon I, Fabbrica D. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol 1992;84:364-71.
23. Cavaletti G, Tredici T, Braga M, Tazarri S. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol 1995;133:64-72.
24. Meregalli C, Canta A, Carozzi VA, Chiorazzi A, Oggioni N, Gilardini A, et al. Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain 2010; 14:343-50.
25. Windebank AJ. Chemotherapeutic neuropathy. Curr Opin Neurol 1999;12:565-71. (Pubitemid 30028616)
26. Quastthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2004;249:9-17. (Pubitemid 34119018)
27. Ocean AJ, Vadhat LT. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 2004;12:619-25. (Pubitemid 39280311)
28. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Periph Nerv Syst 2008;13:27-46. (Pubitemid 351393018)
29. Sioka C, Kyritis AP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 2009;63:761-7.
30. Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 2008;15:3081-94.
31. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4:1086-95. (Pubitemid 41079102)
32. Giannakakou P, Nakano M, Nicolaou KC, O'Brate A, Yu J, Blagosklonny MV, et al. Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci U S A 2002;99:10855-60.
33. McLeod JG, Penny R. Vincristine neuropathy: an electrophysiological and histological study. J Neurol Neurosurg Psychiatry 1969;32: 297-304.
34. Jamieson SM, Liu JJ, Connor B, Dragunov M, McKeage MJ. Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large sized sensory neurons following treatment of rats with paclitaxel. Neurotoxicology 2007;28:1092-8. (Pubitemid 350026583)
35. Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007;204:317-25. (Pubitemid 46330280)
36. Authier N, Balayssac D, Marchand F, Ling B, Zangarelli A, Descoeur J, et al. Animal models of chemotherapy-evoked painful peripheral neuropathies. J Am Soc Exp Neurother 2009;6:620-9.
37. Jimeno A. Eribulin: rediscovering tubulin as an anticancer agent. Clin Cancer Res 2009;15:3903-5.
38. Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, et al. A phase 1 study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 2009;15:4207-12.
39. Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004;64:5760-6. (Pubitemid 39095575)
40. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapyCurr Med Chem Anticancer Drugs 2005;5:65-71.
41. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65. (Pubitemid 38525281)
42. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4:1086-95. (Pubitemid 41079102)
43. Yue Q-X, Liu X, Guo D-AMicrotubule-binding natural products for cancer therapy. Planta Med 2010;76:1037-44.
44. Dumontet C, Sikic BI. Mechanisms of action and resistance to antitubulin agents: microtubule dynamics, drug transport and cell death. J Clin Oncol 1999;17:1061-70. (Pubitemid 29109340)